Raptor Pharmaceutical (NASDAQ:RPTP) Analyst Rating Consensus

Raptor Pharmaceutical (NASDAQ:RPTP) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 6 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. JMP Securities upgrades its rating on Raptor Pharmaceutical (NASDAQ:RPTP). Analysts at the JMP Securities have a current rating of Market Outperform on the shares. The shares were previously rated Market Outperform. The rating by the firm was issued on April 7, 2016.

Raptor Pharmaceutical (NASDAQ:RPTP): According to 5 Analysts, The short term target price has been estimated at $ 7.6.The target price could deviate by a maximum of $2.7 from the forecast price. In the near term, the target price could hit a high of $11 and a low of $ 4.

Raptor Pharmaceutical (NASDAQ:RPTP) witnessed a decline in the market cap on Tuesday as its shares dropped 5.74% or 0.31 points. After the session commenced at $5.41, the stock reached the higher end at $5.41 while it hit a low of $5.07. With the volume soaring to 825,500 shares, the last trade was called at $5.09. The company has a 52-week high of $16.28. The company has a market cap of $434 million and there are 85,306,787 shares in outstanding. The 52-week low of the share price is $2.94.

Raptor Pharmaceuticals Corp. has lost 6.78% in the last five trading days and dropped 2.12% in the last 4 weeks. Raptor Pharmaceuticals Corp. is up 11.87% in the last 3-month period. Year-to-Date the stock performance stands at -2.12%.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *